04:11 PM EDT, 05/15/2025 (MT Newswires) -- Regeneron Pharmaceuticals ( REGN ) said Thursday it won $135.6 million dollars in compensatory damages and $271.2 million in punitive damages in its antitrust case against Amgen ( AMGN ) .

A jury in the U.S. District Court for the District of Delaware found Amgen ( AMGN ) using cross-therapeutic bundled rebates to block Regeneron's cholesterol drug Praluent from competing in the market, Regeneron said in a statement.

Amgen ( AMGN ) allegedly leveraged its anti-inflammatory drugs Enbrel and Otezla to convince pharmacy benefit managers to select its Repatha as the exclusive cholesterol treatment over Praluent, the company said.

"Amgen ( AMGN ) threatened to withhold rebates unless PBMs preferred Repatha and excluded Praluent," the company said in the statement.

Amgen ( AMGN ) didn't immediately respond to a request for comment from MT Newswires.

Regeneron shares rose 2.4% in regular trading Thursday, and Amgen ( AMGN ) gained 3.6%.